Centers | ||
|
|
|
Therapeutic Accelerator Program (TAP) | Presude Life Sciences | Edinburgh Drug Discovery |
Test |
Presude Lifesciences is an integrated drug discovery and development services organization led by biopharma professionals with global experience. Read morePresude is a research driven company with expertise in medicinal chemistry, custom synthesis and... |
Based within the world-leading University of Edinburgh Medical School, Edinburgh Drug Discovery has a track record in successfully translating drug discovery projects from target identification through to clinical evaluation. Key areas of... |
Partnerships |
Events |
Jobs |
The Division of Signal Transduction TherapyA vital asset of the MRC-PPU is the Division of Signal Transduction Therapy (DSTT) which was established in 1998. This division operates as a unique collaboration between scientists in the MRC-PPU (all PIs including Ronald Hay FRS Honorary PI of... View all Johns Hopkins BSi Licenses GCPII Assets from EisaiJohns Hopkins Brain Science Institute ("BSi") has taken a non-exclusive license from Eisai to develop new compounds related to Glutamate Carboxypeptidase II (GCP-II) technology. The new compounds developed under this license will be targeted... View all CWHM/OWH Childhood DiarrheaCWHM signed a joint research agreement in 2010 with the Institute for One World Health to discover and develop new drugs to combat diarrhea, which is the second leading cause of death worldwide in children under age 5. Under the agreement, CWHM... View all |
No EVENTS for listing |
No Job Posts |
